mometasone furoate + desloratadine

Mometasone furoate + desloratadine is a fixed-dose combination of two active pharmaceutical ingredients used primarily for the treatment of allergic rhinitis. Mometasone furoate is a synthetic corticosteroid with potent anti-inflammatory properties, acting mainly by binding to the glucocorticoid receptor and inhibiting the release of pro-inflammatory cytokines and mediators. Desloratadine is a second-generation, non-sedating antihistamine that selectively antagonizes peripheral histamine H1 receptors, thereby reducing symptoms such as sneezing, nasal congestion, itching, and rhinorrhea. The combination aims to provide additive or synergistic effects in controlling both inflammation (via mometasone) and histamine-mediated symptoms (via desloratadine). Clinical studies suggest that this combination may offer greater efficacy in symptom control compared to monotherapy with either agent alone for moderate-to-severe allergic rhinitis[1][3][5].